Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study

Bahl, Amit; Challapalli, Amarnath; Das, Prantik; Sharma, Anand; Bhana, Rajanee; Birtle, Alison Jane; Muthukumar, Dakshinmoorthy; Randhawa, Manreet; Sundar, Santhanam; Prentice, Mark; Bianchini, Diletta; Renninson, Emily; CapoMir, Miguel; Syndikus, Isabel; Jayaprakash, Kamalram Thippu; Elumalai, Thiraviyam; Goodwin, Sarah; Parikh, Omi; White, Paul; Foulstone, Emily

Abstract

89 Background: Darolutamide has authorisation for treatment of metastatic hormone sensitive prostate cancer (MHSPC) in combination with docetaxel chemotherapy and androgen deprivation therapy (triplet therapy) based on ARASENS trial results. The RECOMMEND study is a prospective real-world evaluation (RWE) of clinical outcomes in patients with MHSPC treated with this regimen in the UK. Methods: 318 patients were enrolled from 21 UK centres over 20 months from November 2022. Data cut-off was 14 August 2024. Disease characteristics were evaluated. Descriptive statistics have been used for patient demographics and PSA changes with treatment were analysed. Results: Patients on the study had a median age of 67 (range 38-84) years. Majority of the patients were de novo metastatic (91.2%). 68.2% have a Gleason score ≥8. 76 patients (23.9%) had next generation imaging (NGI) at diagnosis. Performance score was 0 (62.7%) or 1 (37.3%). The distribution of metastases (%) were: bone (84.9), nodal (60.4), lung (12.6) and liver (2.5). The median PSA level was 134 (range 1 to 5628) ng/mL at diagnosis. At the end of docetaxel chemotherapy median PSA was 0.35 ng/mL. PSA response see in the 226 patients who had completed 6 cycles of docetaxel chemotherapy at the data cut-off, PSA 50 was seen in 87.6% (198/226) and PSA 90 in 53.2%. PSA responses in those who only completed 4/5 cycles of docetaxel (n=14) did not significantly differ compared to those who completed all 6 cycles (PSA 50 p=0.445 and PSA 90 p-0.664). At 6 months from darolutamide initiation, quality of life (QoL) data is currently available for 173 patients, of these 88.4% reported either stable or improved QoL and 11.6% had a decline in QoL at the end of chemotherapy. Conclusions: The tolerability and efficacy profile of treatment with ADT+Darolutamide+Docetaxel in MHSPC in the RECOmMEnD study is similar to that reported in the ARASENS trial. The QoL data available for 173 patients to date reports either stable or improved QoL at 6 months for 88.4% cases. This provides important prospective RWE data, enabling patients and clinical teams to make informed choices in this setting.

• Journal Article Type: Article
• Acceptance Date: Jan 7, 2025
• Online Publication Date: Feb 18, 2025
• Publication Date: Feb 10, 2025
• Deposit Date: Mar 25, 2025
• Publicly Available Date: Feb 11, 2026
• Journal: Journal of Clinical Oncology
• Print ISSN: 0732-183X
• Electronic ISSN: 1527-7755
• Publisher: American Society of Clinical Oncology
• Peer Reviewed: Not Peer Reviewed
• Volume: 43
• Issue: 5_suppl
• Pages: 89-89
• DOI: https://doi.org/10.1200/jco.2025.43.5_suppl.89
• Public URL: https://uwe-repository.worktribe.com/output/13832151